Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
12.88
-0.06 (-0.46%)
Aug 5, 2026, 1:10 PM EDT - Market open
Omeros Revenue
Omeros had revenue of $9.89M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $9.89M.
Revenue (ttm)
$9.89M
Revenue Growth
n/a
P/S Ratio
94.67
Revenue / Employee
$56,531
Employees
175
Market Cap
932.19M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 29.87M | -34.96M | -53.93% |
| Dec 31, 2017 | 64.83M | 23.21M | 55.77% |
| Dec 31, 2016 | 41.62M | 28.11M | 208.07% |
| Dec 31, 2015 | 13.51M | 12.97M | 2,406.31% |
| Dec 31, 2014 | 539.00K | -1.06M | -66.31% |
| Dec 31, 2013 | 1.60M | -4.42M | -73.43% |
| Dec 31, 2012 | 6.02M | 1.50M | 33.11% |
| Dec 31, 2011 | 4.52M | 2.42M | 114.92% |
| Dec 31, 2010 | 2.11M | 661.00K | 45.78% |
| Dec 31, 2009 | 1.44M | 274.00K | 23.42% |
| Dec 31, 2008 | 1.17M | -753.00K | -39.16% |
| Dec 31, 2007 | 1.92M | 1.52M | 380.75% |
| Dec 31, 2006 | 400.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 196.12M |
| Arbutus Biopharma | 191.45M |
| Theravance Biopharma | 109.78M |
| Janux Therapeutics | 13.73M |
| Inventiva | 7.94M |
| EyePoint | 7.61M |
| Odyssey Therapeutics | 1.06M |
| Avalo Therapeutics | 59.00K |
OMER News
- 2 days ago - Omeros grants new technology add-on payment status to Yartemlea - TheFly
- 2 days ago - CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA® - Business Wire
- 9 days ago - AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright - TheFly
- 9 days ago - Omeros up 11% to $10.89 after AstraZeneca study failure - TheFly
- 22 days ago - Omeros Corporation Investigated by the Portnoy Law Firm - GlobeNewsWire
- 5 weeks ago - Omeros stock crashes on regulatory setback: buy the dip? - Invezz
- 5 weeks ago - Omeros price target lowered to $33 from $40 at H.C. Wainwright - TheFly
- 5 weeks ago - Omeros announces CHMP adopts negative opinion on MAA for narsoplimab - TheFly